This act requires the Secretary of Health and Human Services, acting through the Assistant Secretary for Preparedness and Response, to implement a program that compels covered distributors of highly pathogenic agents to maintain electronic logbooks of every sale, lease, loan, or transfer. It also creates and maintains a dynamic list of agents that meet the definition of highly pathogenic, with initial development within six months and annual updates thereafter.
The bill adds purchaser verification requirements, data retention, and restricted disclosure, and it establishes a framework for evaluating high-containment laboratories and for creating a federal biosafety and biosecurity team to coordinate federal, state, and local biosafety activities.
At a Glance
What It Does
Establishes a logbook program for HPAs, a dynamic agent list, and explicit sale verification and retention rules. It also sets up oversight mechanisms for high-containment labs and a federal biosafety team.
Who It Affects
Distributors of HPAs, purchasers, public biobanks or repositories, and federal/state public health and safety agencies.
Why It Matters
Strengthens traceability and accountability for transfers of dangerous agents, improves response readiness, and creates centralized oversight for biosafety and biosecurity.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill places a new burden on distributors that transfer highly pathogenic agents by requiring them to maintain an electronic logbook of every sale, lease, loan, or transfer. The logbook must include detailed information about the agent, the purchaser, the intended use, and the transfer details, with a signature from the purchaser and safeguards against misrepresentation.
Purchasers must furnish government-issued identification, allowing the distributor to verify identity before completing a transfer. Logbook entries must be kept for at least three years and the data are restricted in who can access them, with exemptions for public health, safety, and national security reasons only.
The Five Things You Need to Know
The bill requires covered distributors to keep an electronic logbook for each transfer of listed HPAs.
Purchasers must present photo ID and sign the logbook to verify identity.
An initial list of highly pathogenic agents must be developed within six months, with annual updates.
Logbook data are retained for at least three years and disclosures are highly restricted.
The bill also calls for a national evaluation of high-containment labs and a new federal biosafety team.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Program establishment and agent list
The Secretary of Health and Human Services, acting through the Administration for Strategic Preparedness and Response, must carry out a program requiring each covered distributor of a highly pathogenic agent to comply with logbook requirements. The bill also requires the development and maintenance of a list of all agents meeting the definition of highly pathogenic, with an initial list due within six months of enactment and annual updates thereafter. The Secretary must consult with relevant federal agencies and consider the latest biosafety publications when developing and updating the list.
Logbook data requirements
Distributors must maintain an electronic logbook of each sale, lease, loan, or transfer of listed agents, including agent name, purchaser contact details, purchaser’s intended use and housing location, date and time of transfer, and the method of transfer. The logbook format and data fields will be defined by the Secretary to ensure consistency and enforceability.
Sales verification and purchaser identity
For each transfer, the distributor must verify the purchaser’s identity using photo identification and obtain a signed confirmation that includes purchaser name, address, intended use, and transfer details. The distributor must ensure the entered name matches the purchaser’s identification and that the data entered in the logbook are correct.
Retention and disclosure restrictions
Logbook entries must be retained for not less than three years, and a successor entity assumes custody of the logbooks if ownership changes. The Secretary will regulate disclosure, limiting it to public health, safety, law enforcement, or national security purposes, and exempting logbooks from certain FOIA disclosures.
Evaluation of high-containment laboratories
The National Security Advisor, in consultation with multiple federal departments, shall identify a single federal entity to oversee periodic strategic evaluations of high-containment laboratories to assess capacity, security, and oversight needs and to update national standards for design, construction, operation, and maintenance of such labs.
Public Health Biosafety and Biosecurity Team
A Public Health Biosafety and Biosecurity Team shall serve as the single federal point of contact for state, local, Tribal, and territorial officials on biosafety and biosecurity issues related to high-containment laboratories. The team’s duties include coordinating oversight, relating public health impacts, and connecting local officials with the appropriate federal agencies.
Feasibility study and database
The bill directs a feasibility study on establishing a national database of existing high-containment laboratories, including ownership, location, licensing status, and any violations or disciplinary actions. A final report to Congress is required upon completion to inform oversight and policy decisions.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- State and local health departments gain enhanced visibility for outbreak response and regulatory oversight of HPAs.
- Federal biosafety authorities (CDC, NIH, APPR) gain centralized data to monitor compliance and inform policy decisions.
- Publicly funded biobanks and repositories gain a standardized process for transfers, improving traceability.
- Covered distributors benefit from a clear compliance framework that reduces legal risk from illicit transfers.
- Law enforcement and national security agencies improve capabilities to detect and deter improper transactions.
Who Bears the Cost
- Covered distributors incur IT, process changes, and training costs to implement logbooks and verification.
- Purchasers face additional identity verification steps and potential delays in legitimate transfers.
- Small or resource-constrained distributors and research facilities bear higher compliance costs and administrative burden.
- Public health agencies may incur costs to access and analyze logbook data for enforcement and oversight.
- State and local agencies may need to align with new reporting and data-sharing requirements.
Key Issues
The Core Tension
The central dilemma is to strengthen safeguards against illicit transfers without unduly hindering legitimate scientific research and timely public health responses, all while ensuring data privacy and manageable costs for distributors and researchers.
The bill creates a robust framework for tracking transfers of highly pathogenic agents, but it also raises concerns about administrative burdens and potential delays to legitimate scientific work. Balancing rapid access to agents for essential research with stringent safeguards will require careful calibration of the logbook format, data access rules, and enforcement mechanisms.
Data stewardship, privacy considerations, and interoperability with existing regulatory regimes (such as the Federal Select Agent Program) will need ongoing attention as the program is implemented.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.